---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-149590"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2026-04-09T23:59:59+00:00"
generated_at: "2026-05-15T06:47:18.941224+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Galera converts 76.5K Series B preferred into 76.5M common shares; warrants exercised

## Summary
- Converted 76,479.175 Series B Preferred shares into 76,479,164 common shares on April 7, 2026.
- After conversion, 42,839.11 Series B Preferred shares remain outstanding.
- Ikarian Capital affiliates exercised pre-funded warrants for 8,488,229 common shares at $0.001/share on April 8, 2026.
- Remaining pre-funded warrants to purchase 14,552,811 common shares outstanding.

## SEC filing metadata
- accession: 0001193125-26-149590
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2026-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312526149590/0001193125-26-149590-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312526149590/d136871d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-149590
- JSON: https://secwatch.observer/filing/0001193125-26-149590.json
- Plain text: https://secwatch.observer/filing/0001193125-26-149590.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.